AU2000279624A1 - Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient - Google Patents

Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient

Info

Publication number
AU2000279624A1
AU2000279624A1 AU2000279624A AU7962400A AU2000279624A1 AU 2000279624 A1 AU2000279624 A1 AU 2000279624A1 AU 2000279624 A AU2000279624 A AU 2000279624A AU 7962400 A AU7962400 A AU 7962400A AU 2000279624 A1 AU2000279624 A1 AU 2000279624A1
Authority
AU
Australia
Prior art keywords
blooe
antagonist
active ingredient
agent containing
lowering agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2000279624A
Inventor
Norihiro Nishimoto
Kazuyuki Yoshizaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of AU2000279624A1 publication Critical patent/AU2000279624A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2000279624A 2000-10-27 2000-10-27 Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient Abandoned AU2000279624A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2000/007603 WO2002036164A1 (en) 2000-10-27 2000-10-27 Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient

Publications (1)

Publication Number Publication Date
AU2000279624A1 true AU2000279624A1 (en) 2002-05-15

Family

ID=11736635

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2000279624A Abandoned AU2000279624A1 (en) 2000-10-27 2000-10-27 Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient

Country Status (3)

Country Link
US (1) US8173126B2 (en)
AU (1) AU2000279624A1 (en)
WO (1) WO2002036164A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69839992D1 (en) 1997-03-21 2008-10-23 Chugai Pharmaceutical Co Ltd Prophylactic or therapeutic agents for the treatment of multiple sclerosis, with antagonist anti-IL6 receptor antibodies as the active ingredient
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
GB2401040A (en) * 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
US8398980B2 (en) 2004-03-24 2013-03-19 Chugai Seiyaku Kabushiki Kaisha Subtypes of humanized antibody against interleuken-6 receptor
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US20090238825A1 (en) * 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
WO2008144763A2 (en) 2007-05-21 2008-11-27 Alder Biopharmaceuticals, Inc. Antibodies to il-6 and use thereof
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
AU2008254578B2 (en) * 2007-05-21 2013-06-06 Alderbio Holdings Llc Novel rabbit antibody humanization methods and humanized rabbit antibodies
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
PE20091174A1 (en) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd LIQUID FORMULATION WITH HIGH CONCENTRATION OF ANTIBODY CONTENT
DK2297202T3 (en) 2008-05-13 2016-03-21 Novimmune Sa ANTI-IL-6 / IL-6R ANTIBODIES AND PROCEDURES FOR USE THEREOF
US8323649B2 (en) * 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
AU2010311567B2 (en) 2009-10-26 2015-03-26 Chugai Seiyaku Kabushiki Kaisha Method for the production of a glycosylated immunoglobulin
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
EP2504030A4 (en) 2009-11-24 2013-06-26 Alderbio Holdings Llc Antagonists of il-6 to raise albumin and/or lower crp
WO2011130425A1 (en) * 2010-04-13 2011-10-20 Weisenthal Larry M Method to detect endothelial cell massive calcium accumulation death
RU2013126477A (en) 2010-11-08 2014-12-20 Дженентек, Инк. INTEGRATED SCAN ANTIBODIES AGAINST IL-6 RECEPTOR
ES2847891T3 (en) 2010-11-23 2021-08-04 Vitaeris Inc Anti-IL-6 antibodies for the treatment of oral mucositis
JO3370B1 (en) 2011-11-10 2019-03-13 Regeneron Pharma Methods of inhibiting tumor growth by antagonizing il-6 receptor
MX363403B (en) 2013-07-04 2019-03-22 Hoffmann La Roche Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples.
US11484591B2 (en) 2016-02-22 2022-11-01 Ohio State Innovation Foundation Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin A analogues or metabolites, and estradiol metabolites
EP3576790A4 (en) 2017-02-01 2020-12-23 Yale University Treatment of diuretic resistance
CN110603057A (en) 2017-03-17 2019-12-20 俄亥俄州创新基金会 Nanoparticles for delivery of chemopreventive agents
CA3087699A1 (en) 2018-01-05 2019-07-11 Corvidia Therapeutics, Inc. Methods for treating il-6 mediated inflammation without immunosuppression
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2139351C1 (en) * 1991-04-25 1999-10-10 Чугаи Сейяку Кабусики Кайся H- and l-chains of monoclonal antibody pm-1 (monat) to human il-6r receptor and their v-region, modified monat, its h- and l-chains and their v-regions, cdr-sequence, dna-sequence
JPH05148156A (en) * 1991-11-28 1993-06-15 Toray Ind Inc Proliferating agent for vascular endothelical cell
US5888510A (en) * 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
DE69839992D1 (en) * 1997-03-21 2008-10-23 Chugai Pharmaceutical Co Ltd Prophylactic or therapeutic agents for the treatment of multiple sclerosis, with antagonist anti-IL6 receptor antibodies as the active ingredient

Also Published As

Publication number Publication date
US20070243189A1 (en) 2007-10-18
US8173126B2 (en) 2012-05-08
WO2002036164A1 (en) 2002-05-10

Similar Documents

Publication Publication Date Title
AU2000279624A1 (en) Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient
AU2000279625A1 (en) Blood mmp-3 level-lowering agent containing il-6 antgonist as the active ingredient
AU2002210952A1 (en) Preventives or remedies for psoriasis containing as the active ingredient IL-6 antagonist
IL161940A0 (en) Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient
IL157741A0 (en) Pharmaceutical compositions containing an antihyperplastic active agent
AU2001290250A1 (en) Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
AU2002324624A1 (en) Sequestered antagonist formulations
HUP0501186A2 (en) Pharmaceutical compositions comprising active vitamin d compounds
NO20003196L (en) Immediately dissolving dosage formulation
IL229510A0 (en) Dosage form containing pantoprazole as active ingredient
AU2002302544A1 (en) Active ingredient combinations for hair-dyeing agents
IL159345A0 (en) Active ingredient combination for pharmacological addictive substances or intoxicant therapy
AU2001272383A1 (en) Fungicidal combinations of active agents
EP1608395A4 (en) Anticancer agent comprising lk8 protein as an active ingredient
HUP0303636A3 (en) Dihydronaphthalenederivative compounds and pharmaceutical compositions containing them as active ingredient
AU4317500A (en) Antibiral compositions containing phorbol derivatives as the main active ingredient
GB0107751D0 (en) Pharmaceutically active compounds
GB0105893D0 (en) Pharmaceutically active compounds
AU1495802A (en) Fungicidal formulation
GB0106631D0 (en) Pharmaceutically active compounds
AU2001292276A1 (en) Nitrogen-containing compounds and ccr3 inhibitors containing the same as the active ingredient
AU2003259532A1 (en) Ready-to-drink formulation containing an active ingredient
AU2003252660A1 (en) Tocolytic agent comprising ep2 agonist as the active ingredient
AU2002238875A1 (en) Remedies for depression containing ep1 antagonist as the active ingredient
AU2001292258A1 (en) Remedies for hepatic diseases containing calcium channel antagonist as the active ingredient